SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly results beat expectations and raised guidance, with a large revenue backlog and customer prepayments bolstering the AI-compute demand story and easing some financing concerns. The community reaction is split: bulls see stronger execution and potential short covering, while bears remain focused on heavy debt, interest costs and cash burn; the stocks muted, volatile response drew particular attention.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and outlook are driving attention, with traders focused on improved profitability and recurring Samsung and Micron licensing revenue expected to bolster future quarters. The reaction is mostly bullish, though some question the decline in product sales and are disappointed that the call provided no concrete SK Hynix or Nasdaq-uplisting update; speculation about a Hynix deal remains unconfirmed.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the Nov. 22 FDA decision on Capricors deramiocel application for Duchenne muscular dystrophy; management said the application is in final review and described launch preparations. Many traders read CEO Linda Marbns confident Q3-call remarks as encouraging, while others caution that the outcome remains uncertain given FDA concerns and the applications binary risk.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Scrutiny of CEO Jensen Huang over his relationship with a woman alleged to have ties to Chinese intelligenceand questions about Nvidia chip shipments to Chinais driving concern about governance, export controls, and whether Huang could remain CEO; the allegations have not established that company secrets were compromised. Traders are split between viewing the selloff as an oversold buying opportunity ahead of earnings and fearing further fallout from the investigations and shareholder litigation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed expectations, particularly on revenue, prompting a sharp selloff and renewed criticism of its high valuation, cash burn, and slow path to commercialization. Some traders remain optimistic about its quantum technology and long-term prospects, but that view is competing with concerns that technical progress and government support have yet to translate into meaningful business growth.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos announcement of a large special cash dividend and renewed share-buyback authorization is driving the discussion. Many traders welcome the shareholder payout and are bullish on the stock, while others argue the dividend is not free money and that Costcos valuation remains expensive.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: revenue growth, expanding gross margins and raised full-year guidance were offset by an EPS miss and weaker-than-expected adjusted EBITDA, prompting a sharp selloff. Bulls view the reaction as an overreaction to the miss and emphasize the growth outlook, while more cautious traders point to continued losses and near-term risks.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Waves Q3 report is driving the discussion: traders are weighing revenue growth and a sizable backlog against softer bookings, continued losses, and questions about turning orders into revenue, amid a sharp selloff. Bulls point to D-Waves commercial potential and cash reserves, while bears argue its valuation remains stretched and near-term demand is unproven.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Strong Q3 results and another increase to full-year revenue guidance drove a sharp rally in SENS, with traders pointing to accelerating Eversense CGM adoption. The gains then faded, prompting debate between bullish holders who see improving commercial momentum and skeptics citing profit-taking, cash needs, and management or dilution risks.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins quarterly results, particularly improved profitability and a new share-buyback authorization, are driving discussion. Traders are split: some see stronger margins and repurchases as bullish, while others point to declining same-store sales and a muted, range-bound share price; hopes for a U.S. relisting remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.read more...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
CalciMedica (NASDAQ:CALC) shares roseread more...

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

Equity

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 


These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?

Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.

Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday

U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.read more...

Why Is Pharvaris Stock Soaring Tuesday?

Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.read more...

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Pharvaris NV

Bearish Sentiment

<ul class="summary-bullets"><li>BioCryst’s Orladeyo is approved to prevent HAE attacks.&nbsp;</li><li>Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million in revenue from the drug this year.</li><li>BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success.</li></ul><p>Shares of BioCryst Pharmaceuticals (BCRX) fell sharply on Tuesday after a competitor reported strong late-stage results in hereditary angioedema, the rare swelling disorder that underpins BioCryst’s main product.</p><p>BCRX fell 9% on Tuesday and clocked its worst day since late February. &nbsp;</p><h2 class="st-heading-2">A Rival Pill Raises The Bar</h2><p>The pressure came from Pharvaris (PHVS), which said its once-daily experimental pill cut monthly swelling attacks by 83% compared with a dummy treatment in a late-stage study. In the two most common forms of the disease, attacks fell by 87%. The medicine was generally well tolerated, and Pharvaris plans to seek approval in the first half of 2027. PHVS shares jumped 7% in regular trading and another 3% after-hours.</p><p>That market is the same one served by BioCryst’s Orladeyo, an approved once-daily capsule used to prevent attacks. Investors marked down Orladeyo on the risk of a stronger oral rival after 2027.</p><h2 class="st-heading-2">Orladeyo Market</h2><p>Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million from the drug this year. A pellet version for young children has begun shipping after an earlier manufacturing delay. The drug has generated more than $2 billion in revenue since U.S. approval in 2020. BioCryst is also developing a second hereditary angioedema medicine, navenibart, with late-stage data still expected in 2027.</p><p>BioCryst CEO Charlie Gayer <a href="https://stocktwits.com/news-articles/markets/equity/bio-crysts-orladeyo-built-the-cash-pile-ceo-gayer-wants-to-buy-the-next-asset/cZYAopbRJrb">said</a> last month that the company wants to buy rare-disease medicines after Orladeyo's success. Gayer has said the next products should come from outside deals, not its own lab. Larger drugmakers have been chasing bigger assets. BioCryst is positioning itself as a buyer in the rare-disease gap they leave behind.</p><h2 class="st-heading-2">How Did BCRX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around BCRX rose from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume jumped from ‘low’ to ‘high’ levels.</p><p>A Stocktwits user dismissed Tuesday's selloff, noting that the company already has a real commercial product. “I’m really not worried.. it will go up sooner than later.. market trying to get rid of the weak hands,” they said.</p><p><stembedurl>https://stocktwits.com/Ray52baltimore/message/663832998</stembedurl></p><p>Another user opined that no one will switch out of Orladeyo even if Pharvaris’s drug gets approved. It also noted that PHVS is valued higher than BCRX despite having no approved products.</p><p><stembedurl>https://stocktwits.com/SCCT2FL/message/663813354</stembedurl></p><p><a href="https://stocktwits.com/symbol/BCRX">BCRX stock</a> has gained 16% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dal-stock-drops-jefferies-sees-possible-snag-to-in-cabin-experience-owing-to-spcx-vsat-spectrum-fight/cZtE95BRJy5">DAL Stock Drops: Jefferies Sees Possible Snag To In-Cabin Experience Owing To SPCX-VSAT Spectrum Fight</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 

Biocryst Pharmaceuticals Inc.

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Stocktwits Polls

$PHVS Haters will say it is all bios, but it is not. It is exactly quality stocks that get slaughtered. 1.5b MC and I will dip a toe in.

Rainer Zufall

$PHVS  The pellet form of Orladeyo results are basically the same as PHVS, but BCRX already has thorough market penetration.  It seems Pharvaris shares are still way overpriced, and BCRX shares laughably undervalued.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PHVS Pharvaris NV

Fundamentals

Latest PHVS News